These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33410280)

  • 21. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
    Gandotra C; Clark J; Liu Q; Senatore FF; Rose M; Zhang J; Stockbridge NL
    Ther Innov Regul Sci; 2022 Jan; 56(1):4-7. PubMed ID: 34699047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
    Lund LH; Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Kalus S; Ferber PC; Koch C; Maggioni AP;
    Int J Cardiol; 2023 Jan; 370():279-286. PubMed ID: 36216094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
    ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
    Niu CY; Yang SF; Ou SM; Wu CH; Huang PH; Hung CL; Lin CC; Li SY
    J Am Heart Assoc; 2022 Sep; 11(18):e026407. PubMed ID: 36062622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
    J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
    Moon MG; Hwang IC; Choi W; Cho GY; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ
    ESC Heart Fail; 2021 Jun; 8(3):2058-2069. PubMed ID: 33682334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
    Wijkman MO; Claggett B; Vaduganathan M; Cunningham JW; Rørth R; Jackson A; Packer M; Zile M; Rouleau J; Swedberg K; Lefkowitz M; Shah SJ; Pfeffer MA; McMurray JJV; Solomon SD
    Cardiovasc Diabetol; 2022 Jun; 21(1):110. PubMed ID: 35717169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
    Vaduganathan M; Claggett BL; Greene SJ; Aggarwal R; Bhatt AS; McMurray JJV; Fonarow GC; Solomon SD
    JAMA Cardiol; 2021 Dec; 6(12):1415-1423. PubMed ID: 34524394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
    Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
    ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
    Holm N; Bromage DI; Cannata A; DeCourcey J; Bhatti P; Huang M; McDonagh TA
    J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):37-41. PubMed ID: 34632983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Yang Y; Shen C; Lu J; Fu G; Xiong C
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):177-182. PubMed ID: 34711748
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.